Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-9.62%
|
$497,700
$63.74 P/Share
|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,900
+18.71%
|
$18,900
$1.53 P/Share
|
|
Feb 16
2021
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+2.35%
|
-
|
|
Feb 16
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+22.65%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.46%
|
$0
$0.86 P/Share
|
|
Feb 16
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+32.19%
|
-
|
|
Feb 16
2021
|
Howard Horn CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+10.98%
|
-
|
|
Feb 12
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.94%
|
$0
$0.86 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-19.22%
|
$560,900
$71.16 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+16.12%
|
$7,900
$1.53 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$479,136
$69.91 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
31,300
-48.53%
|
$1,502,400
$48.17 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,300
+32.67%
|
$31,300
$1.53 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
10,530
-24.08%
|
$400,140
$38.0 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,530
+19.41%
|
$10,530
$1.53 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-10.28%
|
$110,345
$29.36 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+9.32%
|
$3,805
$1.53 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$180,570
$26.32 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+2.94%
|
$6,945
$1.49 P/Share
|
|
Dec 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+22.25%
|
$9,500
$1.53 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.19 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.27 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$215,295
$31.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,930
-11.0%
|
$87,900
$30.0 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,930
+9.91%
|
$2,930
$1.53 P/Share
|
|
Nov 27
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+11.58%
|
$0
$0.86 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-8.99%
|
$63,180
$27.29 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|
|
Nov 12
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+28.66%
|
$0
$0.86 P/Share
|
|
Nov 10
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-8.99%
|
$60,840
$26.26 P/Share
|
|
Nov 10
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|
|
Nov 04
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.57%
|
$5,000
$1.53 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$215,264
$31.27 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$133,175
$35.04 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,500
-15.5%
|
$595,000
$34.15 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+9.32%
|
$25,000
$2.76 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-19.0%
|
$239,080
$43.03 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+15.97%
|
$5,560
$1.53 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-16.06%
|
$512,500
$41.74 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+12.75%
|
$12,500
$1.55 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$236,130
$34.75 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|
|
Sep 29
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,510
-12.9%
|
$133,380
$38.0 P/Share
|